Sight Sciences (NASDAQ:SGHT - Free Report) had its price target cut by Piper Sandler from $5.50 to $3.50 in a report released on Thursday, Marketbeat Ratings reports. They currently have a neutral rating on the stock.
Several other research analysts have also recently commented on the company. Stifel Nicolaus cut their price target on Sight Sciences from $6.00 to $5.00 and set a "buy" rating on the stock in a research note on Thursday, February 6th. Needham & Company LLC reissued a "hold" rating on shares of Sight Sciences in a research note on Thursday. Lake Street Capital dropped their price target on shares of Sight Sciences from $5.00 to $3.00 and set a "hold" rating on the stock in a research report on Wednesday, January 15th. Citigroup reduced their price objective on Sight Sciences from $4.60 to $3.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, UBS Group lowered their price objective on shares of Sight Sciences from $5.50 to $5.00 and set a "buy" rating on the stock in a research report on Monday, January 27th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $3.83.
Read Our Latest Research Report on SGHT
Sight Sciences Stock Performance
Shares of NASDAQ:SGHT traded up $0.09 during midday trading on Thursday, hitting $2.45. The stock had a trading volume of 679,174 shares, compared to its average volume of 271,457. The company has a market capitalization of $124.35 million, a PE ratio of -2.40 and a beta of 2.52. The stock has a 50 day moving average price of $2.90 and a two-hundred day moving average price of $4.38. Sight Sciences has a 1 year low of $2.17 and a 1 year high of $8.45. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.01). The business had revenue of $19.07 million for the quarter, compared to analysts' expectations of $18.98 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. During the same period last year, the business earned ($0.22) earnings per share. As a group, equities analysts predict that Sight Sciences will post -0.99 earnings per share for the current fiscal year.
Insider Transactions at Sight Sciences
In other Sight Sciences news, CEO Paul Badawi sold 24,819 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $2.92, for a total value of $72,471.48. Following the completion of the sale, the chief executive officer now owns 5,676,331 shares of the company's stock, valued at approximately $16,574,886.52. This represents a 0.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 63,014 shares of company stock worth $197,295 over the last 90 days. 28.90% of the stock is owned by insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. GSA Capital Partners LLP bought a new stake in Sight Sciences during the third quarter worth $136,000. Millrace Asset Group Inc. bought a new position in Sight Sciences in the third quarter valued at about $874,000. Jacobs Levy Equity Management Inc. increased its position in Sight Sciences by 46.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company's stock worth $1,310,000 after purchasing an additional 65,767 shares in the last quarter. State Street Corp increased its holdings in Sight Sciences by 17.4% in the 3rd quarter. State Street Corp now owns 646,776 shares of the company's stock worth $4,075,000 after purchasing an additional 95,843 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Sight Sciences by 317.4% during the third quarter. Barclays PLC now owns 50,300 shares of the company's stock worth $317,000 after purchasing an additional 38,248 shares during the period. 55.51% of the stock is owned by institutional investors and hedge funds.
About Sight Sciences
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
See Also
Before you consider Sight Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.
While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
